Sacrosidase Patent Expiration

Sacrosidase was first introduced by Qol Medical Llc in its drug Sucraid on Apr 9, 1998.


Sacrosidase Patents

Given below is the list of patents protecting Sacrosidase, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sucraid US9255261 Ultrapure hypoallergenic solutions of sacrosidase Feb 07, 2034 Qol Medcl
Sucraid US9469847 Ultrapure hypoallergenic solutions of sacrosidase Feb 07, 2034 Qol Medcl
Sucraid US9849161 Ultrapure hypoallergenic solutions of sacrosidase Feb 07, 2034 Qol Medcl



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sacrosidase's patents.

Given below is the list recent legal activities going on the following patents of Sacrosidase.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 07 Mar, 2024 US9469847
Payment of Maintenance Fee, 8th Yr, Small Entity 25 Jul, 2023 US9255261
Payment of Maintenance Fee, 4th Yr, Small Entity 28 Jun, 2021 US9849161
Payment of Maintenance Fee, 4th Yr, Small Entity 20 Apr, 2020 US9469847
Post Issue Communication - Certificate of Correction 24 Feb, 2020 US9255261
Post Issue Communication - Certificate of Correction 18 Feb, 2020 US9469847
Post Issue Communication - Certificate of Correction 18 Feb, 2020 US9849161
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Aug, 2019 US9255261
Patent Issue Date Used in PTA Calculation 26 Dec, 2017 US9849161
Recordation of Patent Grant Mailed 26 Dec, 2017 US9849161


Sacrosidase's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List